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Association of Increased Plasma Cardiotrophin-1 With
Inappropriate Left Ventricular Mass in
Essential Hypertension
Begon˜a Lo´pez, Jose´ M. Castellano, Arantxa Gonza´lez, Joaquı´n Barba, Javier Dı´ez
Abstract—Inappropriate left ventricular mass is present when the value of left ventricular mass exceeds individual needs
to compensate hemodynamic load imposed by increased blood pressure. The goal of this study was to investigate
whether plasma concentration of cardiotrophin-1, a cytokine that induces exaggerated hypertrophy in cardiomyocytes
with hypertensive phenotype, is related to inappropriate left ventricular mass in patients with essential hypertension. The
study was performed in 118 patients with never-treated hypertension and without prevalent cardiac disease. The left
ventricular mass prediction from stroke work (systolic blood pressureDoppler stroke volume), sex, and height (in
meters2.7) was derived. An observed left ventricular mass/predicted left ventricular mass value 128% defined
inappropriate left ventricular mass. Plasma cardiotrophin-1 was measured by an enzyme-linked immunosorbent assay.
The studies were repeated in a group of 45 patients after 1 year of antihypertensive treatment. At baseline 67 and 51
patients presented with appropriate and inappropriate left ventricular mass, respectively. Plasma cardiotrophin-1 was
higher (P0.001) in patients with inappropriate mass than in patients with appropriate mass and normotensive controls.
A direct correlation was found between cardiotrophin-1 and observed left ventricular mass/predicted left ventricular
mass ratio (r0.330, P0.001) in all hypertensive patients. After treatment, plasma cardiotrophin-1 decreased and
increased in patients in which inappropriate left ventricular mass regressed and persisted, respectively, despite a similar
reduction of blood pressure in the 2 subgroups of patients. Albeit descriptive in nature, these results suggest the
hypothesis that an excess of cardiotrophin-1 may contribute to inappropriate left ventricular growth in
hypertensive patients. (Hypertension. 2007;50:977-983.)
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The term inappropriate left ventricular mass (iLVM) hasbeen applied to conditions in which the observed level of
LVM exceeds the theoretical value predicted by sex, body size,
and stroke work.1–3 iLVM is associated with LV concentric
geometry, and systolic and diastolic dysfunction, even in the
absence of traditionally defined LV hypertrophy (LVH).4–6 In
addition, iLVM appears to be a marker of adverse cardiovascular
prognosis independent of LVH.1,7 Recent data suggest that
changes in the appropriateness of LVM from baseline to
follow-up during treatment may predict a subsequent cardiovas-
cular event in hypertensive patients.8
Cardiotrophin-1 (CT-1) is a member of the interleukin
(IL)-6 superfamily,9 which induces cardiomyocyte growth.10
Of interest, we have shown recently that CT-1 exerts exag-
gerated growth responses in cardiomyocytes from adult
spontaneously hypertensive rats (SHR) compared with car-
diomyocytes from adult Wistar rats.11 Other studies have
shown that CT-1 expression is abnormally increased in the
hypertrophied left ventricle of hypertensive rats.11–13 Re-
cently, it has been reported that plasma CT-1 is increased in
hypertensive patients, namely in those with LVH.14,15 Fur-
thermore, an association has been found between treatment-
induced decrease of plasma CT-1 and LVH regression in
hypertensive patients.16
It has been proposed that the process that yields iLVM can
be mediated by cytokines among other nonhemodynamic
factors.17 Thus, we have hypothesized that CT-1 may be
abnormally upregulated in hypertensive patients with iLVM.
To test this hypothesis, plasma CT-1 was determined in
normotensive subjects and never treated hypertensive patients
with either appropriate LVM (aLVM) or iLVM. In addition,
the relationship of plasma CT-1 with iLVM was further
analyzed in a subgroup of hypertensive patients after 1 year of
antihypertensive treatment.
Methods
Subjects
All subjects gave written informed consent to participate in the study
and the institutional review committee approved the study protocol.
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The study conformed to the principles of the Helsinki Declaration.
The study population consisted of 118 hypertensive patients with
sitting systolic and sitting diastolic blood pressure of more than 139
and 89 mm Hg, respectively. All patients had appropriate clinical
and laboratory evaluation to exclude secondary hypertension and
none of them had received previous treatment with antihypertensive
drugs. Other cardiac diseases associated with LVH (eg, hypertrophic
cardiomyopathy and aortic stenosis) were excluded on echocardiog-
raphy. No patient exhibited clinical manifestations of ischemic heart
disease or heart failure.
Fifty-six from the 118 initially enrolled patients agreed to receive
antihypertensive treatment prescribed by their family doctors in
accordance with the 2003 European Society of Hypertension–
European Society of Cardiology guidelines and to continue the
study.18 The family doctors were blind to the presence or absence
of iLVM in their patients. Forty-five of these patients reached
1 year of follow-up and were considered eligible for complete
medical examination, including echocardiography and biochemical
determinations.
A group of 31 normotensive subjects (23 men and 8 women; mean
age, 55 years; range, 40 to 68 years) were used as control subjects for
biochemical studies. These controls were subjects without iLVM and
without clinically proven cardiac disease.
Assessment of LVM and Function
Two-dimensional echocardiographic imaging, targeted M-mode re-
cordings, and Doppler ultrasound measurements were obtained in
each patient as previously reported.14 The LVM was calculated in
accordance with the Penn convention (LVM1.04 [(interventricular
septal thickness (IVST)posterior wall thickness (PWT)LV inter-
nal diameter)3LV internal diameter3]13.6) and normalized by
height2.7.19 LVH was defined by sex-specific partition values, as
LVM index (LVMI)49.2 g/m2.7 for men and 46.7 g/m2.7 for
women.19 Relative wall thickness (RWT) was calculated as PWT/LV
internal radius. LV concentric geometry was defined as RWT 0.44.
LV end-diastolic volume (LVEDV) was calculated using Teichholz
formula. Stroke volume was generated from Doppler interrogation of
transaortic flow at the aortic annular level and aortic cross-sectional
area. Stroke work (SW) was therefore computed using systolic blood
pressure, as previously reported.2 An equation to predict compensatory
LVM [predicted LVM55.376.64height2.70.65SW18.07
sex, where male gender is 1 and female gender is 2] was used in
accordance with de Simone et al.7 The value of LVM directly measured
from echocardiograms was divided by that predicted by the above
equation and LVM was expressed as a percent of predicted (%LVM),
representing the excess relative to the “compensatory” value (ie, 100%
of predicted). iLVM was defined as 128% of the predicted value (ie,
%LVM 128%).2
LV systolic function was estimated at the chamber level, by
computation of ejection fraction (EF) from Doppler stroke volume
divided by LVEDV, and at the midwall as midwall fractional
shortening (MWS) as both absolute and corrected for circumferential
end-systolic stress (ESS).20 Systolic dysfunction was defined as EF
50% and 30%,21 or as ESS-corrected MWS 89.2%.22
The following pulsed Doppler measurements of the mitral inflow
were obtained: maximum early transmitral velocity in diastole (VE),
maximum late transmitral velocity in diastole (VA), the deceleration
time of the early mitral filling wave (DT), and isovolumic relaxation
time (IVRT). As a normal VE/VA ratio is strongly dependent on age
and heart rate, its raw value was normalized by the following
equation23:
VE/VAadjVE/VA[0.0199(age50)
[0.0082(heart rate75)]
A value of VE/VAadj (0.66) or a value of IVRT greater than 100
ms or a value of DT greater than 220 ms were used to identify
abnormal LV relaxation.23
Measurement of Plasma CT-1 and Serum
Amino-Terminal Pro-Brain Natriuretic
Peptide (NT-proBNP)
Blood samples were taken at 08:30 hour with all the subjects being
in fasting conditions. Plasma CT-1 was measured by an enzyme-
linked immunosorbent assay (ELISA) as previously reported.14 The
interassay and intraassay coefficients of variations were 6.9 and
7.4%, respectively. The sensitivity was 2.9 fmol of CT-1/mL. The
upper limit for plasma CT-1 values measured in controls was of 41
fmol/mL. NT-proBNP was measured in serum samples by ELISA
according to Karl et al.24 The interassay and intraassay coefficients
of variation were lower than 2%.
Statistical Analysis
The differences between the 2 subgroups of untreated hypertensives
at baseline and between the subgroups of treated hypertensives after
treatment were tested by a Student t test for unpaired data once
normality was demonstrated (Shapiro–Wilks test); otherwise, a nonpara-
metric test (Mann–Whitney U test) was used. To analyze the differences
between the normotensive group and the 2 subgroups of untreated
hypertensive patients at baseline, a 1-way analysis of variance followed
by a Student—Newman–Keuls test was performed once normality was
checked (Shapiro–Wilks test); otherwise, the nonparametric Kruskal–
Wallis test followed by a Mann–Whitney U test (adjusting the
-level for Bonferroni inequality) was used. Differences between
hypertensives before and after treatment were tested by a Student t
test for paired data once normality was demonstrated (Shapiro–Wilks
test); otherwise, a nonparametric test (Wilcoxon test) was used.
Categorical variables were analyzed by the chi-square (2) Fisher
exact test when necessary. Plasma CT-1 was normalized by loga-
rithmic transformation for the correlational analysis. Correlations
were estimated by Spearman correlation coefficients. Partial corre-
lation coefficients were calculated after adjustment for potential
confounding factors. Values are expressed as meanSEM. A value
of P0.05 was considered statistically significant.
Results
Baseline Clinical and
Echocardiographic Characteristics
Hypertensive patients were divided into 2 subgroups accord-
ing to the presence (n51) or absence (n67) of iLVM at
baseline. Table 1 shows the clinical and echocardiographic
parameters assessed in the 2 subgroups of patients. No
differences in blood pressure were found between the 2
subgroups of patients. Body mass index, LVM, LVMI, RWT,
and LVEDV were higher in hypertensives with iLVM than
in hypertensives with aLVM. LVH was present in 39% and
76% of patients with aLVM and iLVM, respectively, this
difference being statistically significant (P0.001). The
prevalence of concentric LV geometry was higher (P0.01)
in patients with iLVM (63%) than in patients with aLVM
(36%).
ESS was higher and ESS-corrected MWS and EF were
lower in hypertensives with iLVM than in hypertensives with
aLVM. Whereas the VE/VAadj ratio was diminished in hyper-
tensives with iLVM compared with hypertensives with
aLVM, no significant differences in either DT or IVRT were
observed between the 2 subgroups of patients.
The observed LVM/predicted LVM ratio was inversely
correlated with ESS-corrected MWS (r0.530, P0.001;
Figure 1A) and EF (r0.368, P0.005; Figure 1B) in all
hypertensives. In addition, significant associations were
found between iLVM and myocardial systolic dysfunction
(210.29, P0.001) and LV systolic dysfunction (25.44,
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P0.05) in all hypertensives. No associations were found
between observed LVM/predicted LVM ratio and parameters
assessing diastolic function.
Baseline Plasma CT-1 and NT-proBNP
Plasma CT-1 was significantly increased in the whole group
of hypertensives (data not shown) and in each subgroup of
hypertensives compared with normotensives (Figure 2). Fur-
thermore, CT-1 was higher in hypertensives with iLVM than
in hypertensives with aLVM (Figure 2).
Plasma CT-1 directly correlated with the observed LVM/
predicted LVM ratio (r0.330, P0.01; Figure 3) and with
LVMI (r0.483, P0.001) in all hypertensives. The corre-
lation between CT-1 and the observed LVM/predicted LVM
ratio remained significant when we excluded the influence of
body mass index (r0.322, P0.005), LVEDV (r0.318,
P0.001), MWS (r0.394, P0.001), ESS (r0.383,
P0.001), ESS-corrected MWS (r0.371, P0.001), EF
(r0.385, P0.001), VE/VAadj (r0.369, P0.001), and
concentric LVH (r0.287, P0.05) in partial correlation
analysis.
Significant associations were found between abnormally
high CT-1 and the presence of iLVM (24.08, P0.05),
myocardial systolic dysfunction (23.49, P0.05), LV
systolic dysfunction (25.62, P0.05), and abnormal LV
relaxation, ie, prolonged IVRT, (24.07, P0.05) in all
hypertensives.
No significant differences were found in the values of
NT-proBNP between the whole group of hypertensives and
the group of normotensives (619 versus 567 pg/mL), and
between hypertensives with aLVM and hypertensives with
iLVM (6611 versus 558 pg/mL).
Findings After Treatment
After 1 year of antihypertensive treatment the patients were
classified in 4 subgroups: patients with baseline aLVM in
which aLVM persisted (n14, subgroup 1) or in which
iLVM developed de novo (n2, subgroup 2) after treatment,
and patients with baseline iLVM in which iLVM regressed
Table 1. Clinical and Echocardiographic Parameters Assessed
in Hypertensive Patients With and Without Inappropriate Left
Ventricular Mass at Baseline
Parameter aLVM iLVM
Age, y 581 591
Gender, m/f 40/27 33/18
BMI, kg/m2 27.10.6 30.30.6*
SBP, mm Hg 1512 1493
DBP, mm Hg 941 921
HR, beats/min 70.11.6 69.11.4
LVM, g 177.45.9 246.610.*
LVMI, g/h2.7 46.61.7 61.72.5*
RWT 0.400.01 0.480.02*
LVEDV, mL 119.43.8 132.96.5†
oLVM/pLVM ratio 1.090.02 1.520.0*
MWS, % 16.90.32 14.90.30*
ESS, Kdynes/cm2 232.38.5 254.111.3†
ESS-corrected MWS, % 95.51.9 84.91.8*
EF, % 63.60.9 60.41.2†
Stroke volume, mL/beat 74.92.5 78.93.6
Stroke index, mL/beat per m2 2.850.12 2.970.17
VE/VAadj 1.060.02 0.980.03†
DT, ms 226.25.3 224.47.3
IVRT, ms 104.33.6 107.46.5
aLVM indicates appropriate left ventricular mass; iLVM, inappropriate LVM;
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HR, heart rate; LVMI, left ventricular mass index; RWT, relative wall
thickness; LVEDV, left ventricular end-diastolic volume; oLVM/pLVM, observed
LVM/predicted LVM; MWS, mid-wall fractional shorting; ESS, circumferential
end-systolic stress; EF, ejection fraction; VE, maximum early transmitral velocity
in diastole; VA, maximum late transmitral velocity in diastole; DT, deceleration
time; IVRT, isovolumic relaxation time.
*P0.001, †P0.05, compared with hypertensives with appropriate LVM.
Figure 1. Inverse correlations between
the baseline observed left ventricular
mass/predicted left ventricular mass
(oLVM/pLVM) ratio and baseline circum-
ferential end-systolic stress-corrected
midwall fractional shortening (ESS-
corrected MWS) (y28.17x126.82;
left panel), and baseline ejection fraction
(EF) (y10.18x75.24) (right panel) in
all untreated hypertensives.
Figure 2. Baseline plasma concentration of cardiotrophin-1
(CT-1) in normotensives, untreated hypertensives with appropri-
ate left ventricular mass (HT-aLVM), and untreated hyperten-
sives with inappropriate LVM (HT-iLVM). Bars represent
meanSEM.
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(n20, subgroup 3) or persisted (n9, subgroup 4) after
treatment. Because of the low number of patients in subgroup
2, only the final data assessed in patients from the remaining
subgroups are presented in Table 2. Whereas most patients in
subgroups 1 and 3 (82% and 94%, respectively) received the
angiotensin type II receptor blocker losartan with or without
hydrochlorothiazide as treatment, most patients (78%) in
subgroup 4 were treated with the -blocker atenolol with or
without hydrochlorothiazide, these differences being signifi-
cant (25.89, P0.05).
Whereas systolic blood pressure was lower in subgroup 4
than in subgroup 1, no differences in diastolic blood pressure
were observed among the 3 subgroups of patients. The heart
rate was lower in subgroup 4 than in subgroups 1 and 3. The
LVMI was higher in subgroup 4 than in subgroups 1 and 3.
Although the ESS-corrected MWS did tend to be lower in
subgroup 4 than in subgroups 1 and 3, the differences did not
reach statistical significance. The EF was lower in subgroup
4 than in subgroups 1 and 3. Although the VE/VAadj did tend
to be lower in subgroups 3 and 4 than in subgroup 1, the
differences did not reach statistical significance. No signifi-
cant differences in NT-proBNP were observed among the
three subgroups of hypertensives (data not shown).
As shown in Figure 4, values of plasma CT-1 remained
unchanged after treatment in subgroup 1, decreased by 21%
after treatment in subgroup 3, and increased by 31% after
treatment in subgroup 4. Thus, final values of CT-1 were
higher in subgroup 4 than in subgroups 1 and 3. A direct
correlation (r0.452, P0.01) was found between final
values of plasma CT-1 and final values of the observed
LVM/predicted LVM ratio in all treated hypertensives (Fig-
ure 5). In addition, an association was found between de-
crease of plasma CT-1 to normal values and reduction of the
observed LVM/predicted LVM ratio to normal values in all
treated hypertensives (24.08, P0.05).
Discussion
The main findings of this study are as follows: (1) CT-1 is
associated with iLVM in patients with essential hypertension;
and (2) CT-1 is associated with systolic and diastolic dys-
function in hypertensive patients.
As stated by de Simone G et al,17 the biological process
that yields iLVM is probably linked to the protracted activity
over time of biological mediators of LVH, such as proto-
oncogenes and other growth factors, neurohormones, and
cytokines, inducing structural modifications that initially
compensate imposed overload but eventually change the
structure and function of LV myocardial tissue. In this regard,
although weak, the correlation found between CT-1 and the
oLVM/pLVM ratio and its independence from concentric
LVH suggest that CT-1 may be one of the cytokines involved
in the development of iLVM. Furthermore, the observation
that CT-1 was increased in those treated patients in which
iLVM persisted despite normalization of blood pressure with
treatment adds support to the above possibility.
Some experimental and clinical observations suggest that
CT-1 may contribute to exaggerated LV growth in hyperten-
sion. We have shown recently that hypertrophy induced by
CT-1 is higher in cardiomyocytes from adult SHR than in
cardiomyocytes from adult normotensive Wistar rats and that
an exaggerated expression of myocardial CT-1 is temporally
associated with cardiomyocyte hypertrophy during the devel-
opment of LVH in adult SHR.11 On the other hand, an
association between LVH and high plasma levels of CT-1 has
been reported in hypertensive patients.14,15 Furthermore, re-
gression of LVH and diminution of plasma levels of CT-1 are
associated in treated hypertensive patients.16
The associations of CT-1 with ESS-corrected MWS and
EF here reported suggest that CT-1 can be involved in
Figure 3. Direct correlation between baseline plasma
cardiotrophin-1 (CT-1) and baseline observed left ventricular
mass/predicted left ventricular mass (oLVM/pLVM) ratio
(y0.0021.16) in all untreated hypertensives.
Table 2. Main Clinical, Echocardiographic, and Biochemical
Parameters Assessed After Antihypertensive Treatment in
Hypertensive Patients Classified in Accordance With the
Response of Left Ventricular Mass to Treatment
Parameter Persisted aLVM Regressed iLVM
Persisted
iLVM
Treatment*
Losartan, n 11 19 2
Atenolol, n 3 1 7
Hydrochlorothiazide, n 5 8 4
SBP, mm Hg 1475 1383 1275†
DBP, mm Hg 872 842 832
HR, beats/min 663 683 502‡
LVMI, g/h2.7 48.63.3 48.63.3 58.33.5§
RWT 0.400.02 0.420.01 0.450.02
oLVM/pLVM ratio 1.030.05 1.020.04 1.490.06‡
ESS-corrected MWS, % 94.53.2 92.12.8 85.64.3
EF, % 63.51.3 63.81.3 58.42.1
VE/VAadj 1.020.09 0.930.04 0.920.08
aLVM indicates appropriate left ventricular mass; iLVM, inappropriate LVM;
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate;
LVMI, LVM index; RWT, relative wall thickness; oLVM/pLVM, observed LVM/
predicted LVM; ESS, circumferential end-systolic stress; MWS, mid-wall
fractional shorting; EF, ejection fraction; VE, maximum early transmitral velocity
in diastole; VA, maximum late transmitral velocity in diastole.
*P0.05 for the distribution of antihypertensive medications among groups;
†P0.01 compared with the subgroup of patients in which persisted aLVM;
‡P0.001, §P0.01, P0.05, compared with the other 2 subgroups of
hypertensives.
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systolic dysfunction present in hypertensive patients, namely
those with iLVM. Several experimental and clinical observa-
tions support this possibility. We found recently enhanced
ERK5 activation by CT-1 in cardiomyocites from SHR
compared with cells from Wistar rats.11 Interestingly, it has
been shown that cardiac-specific overexpression of activated
ERK5 in transgenic mice resulted in contractile heart fail-
ure.25 It has been reported in heart tissues reconstituted from
neonatal rat cardiomyocytes that long-term exposure to CT-1
significantly depressed basal force of contraction and the
inotropic response to Ca2 and isoprenaline,26 thus suggesting
that a chronic excess of the cytokine may induce ineffective
force generation by the cardiac muscle. Finally, CT-1 has
been reported to be increased in the myocardium27,28 and
plasma29,30 of heart failure patients in relation to the severity
of LV systolic dysfunction.
The question arises as to the mechanisms determining the
excess of CT-1 in hypertensive patients with iLVM. Our
finding that ESS was higher in hypertensives with iLVM than
in hypertensives with aLVM suggests a role for mechanical
afterload. This is supported by previous experiments showing
that myocardial CT-1 release is stimulated by ventricular
stretch/pressure.15 Nevertheless, nonhemodynamic factors
may be also involved in upregulation of CT-1. For example,
data from studies with isolated cardiomyocyte and cardiac
fibroblast clearly demonstrate that CT-1 synthesis and release
results from the action of angiotensin II through the AT1
receptor.11,31 In this regard, we report here that treatment with
losartan was associated with reduction in plasma CT-1 in
those hypertensives with high baseline values of the cytokine
and in which iLVM regressed after treatment. The finding
that CT-1 increases in hypertensive patients receiving ateno-
lol as treatment in which iLVM persisted is difficult to
interpret. Norepinephrine has been shown to induce CT-1 in
cardiac cells both at the mRNA32 and protein33 level. How-
ever, because no data are available on the involvement of the
-or the -adrenergic receptor in such stimulation, no pre-
diction on the effect of -blockers on plasma CT-1 can be
made.
Elevated circulating NT-proBNP levels have been found
associated with LVH and cardiac dysfunction in population
studies34,35 and hence this peptide has been proposed as a
marker of hypertrophy and dysfunction whatever is the
underlying cardiac condition. However, our results demon-
strate that, in contrast to CT-1, no association exists between
NT-proBNP and iLVM in hypertensive patients either at
baseline or after treatment. Thus, the possibility exists that
plasma CT-1 is a more sensitive and specific biomarker than
NT-proBNP for detection of the inappropriateness of LVM
and LV dysfunction in hypertension.
Limitations of the Study
First, the baseline study involved a relatively small number of
hypertensive patients. However they were all never-treated
patients which allowed us to exclude any influence of the
antihypertensive treatment on the appropriateness of LVM.
Second, the interventional study was a nonrandomized, open-
label, pilot study involving few patients and heterogeneous
treatment, but because of the nature of the hypothesis under
investigation this design is adequate. Third, although it has
been shown that the human heart secretes CT-1 via the
coronary sinus into the peripheral circulation,36 given the
earlier evidence showing that CT-1 mRNA is expressed in
other organs, there may be additional potential sources of
Figure 4. Plasma concentration of
cardiotrophin-1 (CT-1) at baseline and
after 1 year of treatment in hypertensives
with appropriate left ventricular mass
(aLVM) at baseline and after treatment
(left panel), hypertensives with inappro-
priate LVM (iLVM) at baseline and aLVM
after treatment (middle panel), and
hypertensives with iLVM at baseline and
after treatment (right panel). Bars repre-
sent meanSEM. *P0.05 vs baseline
values in hypertensives with aLVM at
baseline and after treatment.
Figure 5. Direct correlation between plasma cardiotrophin-1
(CT-1) after treatment and the observed left ventricular mass/
predicted left ventricular mass (oLVM/pLVM) ratio after treat-
ment (y0.4570.33) in all treated hypertensives.
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circulating CT-1. Fourth, the correlation between CT-1 and
the observed LVM/predicted LVM ratio was weak, which
means that a small fraction of variability of this parameter is
explained by CT-1. However, additional partial correlation
analysis showed that correcting for other parameters does not
weaken this correlation. This reinforces the possibility that
CT-1 plays a modest but direct role on the development of
iLVM in hypertensive patients and probably in its response to
the antihypertensive treatment. Finally, our findings do not
necessarily conflict with previous experiments demonstrating
survival effects of CT-1 on cardiomyocytes submitted to
acute stress conditions.37,38 In the short run, CT-1 obviously
helps to preserve myocardial integrity; in the long run,
however, it may induce both abnormal growth and dysfunc-
tion of the LV myocardium.
Perspectives
The present study supports the hypothesis that a chronic
excess of CT-1 in association with other hemodynamic and
nonhemodynamic factors may contribute to inappropriate LV
growth and dysfunction in essential hypertension. Thus,
beside an ECG or an echocardiogram, the measurement of
plasma CT-1 could be an additional useful tool in the initial
cardiac assessment of hypertensive patients. In particular, it
might have clinical relevance in identifying those patients
with iLVM and asymptomatic cardiac dysfunction which
may be prone to progress to heart failure and other cardio-
vascular complications. However, before CT-1 is introduced
in clinical practice, data are needed from a large cohort of
patients with respect to its sensitivity and specificity, as well
as its positive and negative predictive value in the detection
and regression of iLVM.
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